GILD Stock Recent News

Gilead Sciences said on Wednesday it has granted royalty-free licenses to six generic drug manufacturers to make and sell cheaper copycat versions of its HIV prevention medicine in 120 low and lower-middle income countries.

-  Non-exclusive voluntary license agreement enables the manufacture and distribution of lenacapavir for HIV prevention and treatment of heavily treatment-experienced patients with multi drug-resistant HIV HYDERABAD, India , Oct. 2, 2024 /PRNewswire/ -- Hetero, India's leading pharmaceutical company with the widest global reach, today announced a new partnership with Gilead Sciences Ireland UC (Gilead Sciences, (Nasdaq: GILD)), a non-exclusive, royalty-free voluntary licensing agreement to manufacture and distribute lenacapavir in 120 primarily low- and lower- middle income countries (LMICs). This agreement will broaden access to lenacapavir, the innovative HIV treatment used in combination with other antiretrovirals and will support efforts to prevent HIV through pre-exposure prophylaxis (PrEP).

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that it has signed non-exclusive, royalty-free voluntary licensing agreements with six pharmaceutical manufacturers to make and sell generic lenacapavir, subject to required regulatory approvals, in 120 high-incidence, resource-limited countries, which are primarily low- and lower-middle income countries. The agreements were signed in advance of any global regulatory submissions to enable these countries.

In the closing of the recent trading day, Gilead Sciences (GILD) stood at $83.94, denoting a +0.12% change from the preceding trading day.

In the closing of the recent trading day, Gilead Sciences (GILD) stood at $83.79, denoting a -0.24% change from the preceding trading day.

CRISPR Therapeutics is still in its early stages of growth. Gilead Sciences remains an underrated stock.

Zacks.com users have recently been watching Gilead (GILD) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Gilead Sciences (GILD) stock price has staged a strong comeback this year, helped by strong earnings and a recent $40 million settlement with American authorities. It has risen for two consecutive weeks, reaching a high of $84, its highest point since January and a few points below its all-time high of $89.

The latest trading day saw Gilead Sciences (GILD) settling at $83.08, representing a -0.1% change from its previous close.

GILD reports the success of its twice-yearly injectable HIV-1 capsid inhibitor, lenacapavir, in a second late-stage study for the prevention of HIV.